Tag: commercialization

—

by

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. The next-generation obesity drugs push weight-loss efficacy along three vectors: triple agonists (retatrutide), oral small molecules (orforglipron), and amylin combinations (CagriSema). At the top end, retatrutide’s…

The honest TRL of post-CMOS: the gap between headline qubit counts and the “when is it useful?” question

—

by

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. For post-CMOS alternatives (quantum, neuromorphic, photonic and others), the real question is not “does it work?” but “when does it become useful?” The estimated resources to break RSA-2048 have…

What died is not Moore’s Law but its economics

—

by

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. Computing-power series, Part 3. The 30-second version What. The real bottleneck hidden behind the “node in nm” headline is not physics but economics — density keeps rising, but the decline in cost-per-transistor ($/transistor)…

Power is the bottleneck — what actually fills AI’s 2028-2030 electricity gap

—

by

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. AI compute demand doubles roughly every 5-6 months, and the binding constraint on scaling has shifted from silicon efficiency to physical grid capacity. A data center takes 2-3 years…

The headline metric is rarely the bottleneck — one structure shared by nine deep-tech results

—

by

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. A cross-domain synthesis, not a single-paper analysis. Information only — not investment advice. The 30-second version What. Across nine seemingly unrelated deep-tech results we covered over two weeks — blood-pressure drugs and a heart-failure polypill, an ECG-AI biomarker, a…

A compiler for the wiring between error-correcting codes — a theory-layer step, not a hardware milestone

—

by

in Quantum

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. A new preprint (Benhemou & Berthusen, arXiv, 2 July 2026) gives an automated way to design the logical gate — a logical CNOT or CZ — that connects two…

Two roads to unconventional superconductivity in one week — and why the first question is evidence, not mechanism

—

by

in Materials

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. Two arXiv preprints within days of each other approach superconductivity from opposite ends. One is experimental — a new material (the chiral topological semimetal Ag2Pd3S) reported to be an…

Three reactors went critical on deadline — but every one of them was zero-power

—

by

in Energy

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. The US Department of Energy’s Reactor Pilot Program (created by Executive Order 14301) set a target of three advanced reactors reaching criticality by 4 July 2026, using a DOE…

How far has noninvasive “brain-to-text” really come? Reading the headlines against the fine print

Jul 6, 2026

—

by